Effectiveness of Bupropion in Treating Marijuana Dependent Individuals

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-03-31

Study Completion Date

2006-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. Bupropion (Zyban) is a medication currently used to treat withdrawal symptoms associated with tobacco use. The purpose of this study is to determine if bupropion will help individuals stop using marijuana.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Bupropion for Treating Nicotine Dependence in Young People

NCT00129272

Tobacco Use Cessation Tobacco Use Disorder

COMPLETED PHASE2

Bupropion and Weight Control for Smoking Cessation - 1

NCT00006170

Tobacco Use Disorder

COMPLETED PHASE4

Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence

NCT00304707

Smoking Cessation Alcohol-Related Disorders

COMPLETED PHASE3

Bupropion as an Adjunct to the Nicotine Patch Plus CBT

NCT00142831

Tobacco Use Disorder

COMPLETED PHASE4

Nabilone & Marijuana Addiction

NCT01025700

Marijuana Smoking

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. This syndrome includes alterations in mood, sleep disturbances, and cognitive performance. Many of nicotine's withdrawal symptoms are similar to those observed with marijuana withdrawal. Bupropion has been shown to be effective in treating nicotine addiction.The purpose of this study is to determine if bupropion is effective in treating marijuana dependent individuals. Specifically, this study will determine if bupropion alleviates withdrawal symptoms associated with marijuana abuse.

Participants in this 21-day, double-blind study will be randomly assigned to receive either bupropion or placebo. Treatment with bupropion will occur for one week before stopping marijuana use (quit day). Bupropion will be administered at 150 mg per day for 3 days, followed by 300 mg per day for the remainder of the study. Quit day will occur on Day 8, at which time participants will be required to remain abstinent from marijuana for the duration of the study. Participants will provide daily urine specimens. Changes in vigilance, memory, reaction time, and psychomotor performance as well as withdrawal symptoms will be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Marijuana Abuse Substance-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type PLACEBO_COMPARATOR

Bupropion

Intervention Type DRUG

150 mg, twice a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bupropion

150 mg, twice a day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Zyban

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Current marijuana use and dependence
* Marijuana use of at least 5 times in the past 7 days or more than 25 times per month for the 3 years prior to enrollment
* Unsuccessful in a previous attempt to quit marijuana

Exclusion Criteria

* Axis I disorder
* Any drug abuse or dependence other than marijuana
* Currently taking antipsychotic or antidepressant medication
* Heavy alcohol drinker (more than 20 drinks per week)
* Current nicotine dependence
* History of a seizure disorder
* Current or prior eating disorder (e.g., bulimia or anorexia nervosa)
* Heavy caffeine use (more than 300 mg per day)
* Life threatening or unstable medical illness
* Pregnant

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No